‘Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers
2012-2022’ analyses the top 14 companies involved in the needle free injection
(NFI) device market. This report also provides sales forecasts, market share
analyses, discussions of technological developments and analyses of commercial
drivers and restraints, including SWOT analysis of the overall NFI device
market. There are over 38 tables and figures included. The result is
comprehensive profiles on the leading companies operating in the NFI device
market with detailed analyses and informed opinion to benefit your work.
Visiongain has determined that the value of the global Needle-Free Injection
Device market will reach $4.49bn in 2022.
What makes this report unique?
Visiongain consulted widely with industry experts and full transcripts from
these exclusive interviews are included in the report. As such, our reports
have a unique blend of primary and secondary sources providing informed
opinion. The report provides insight into key drivers and restraints facing
the industry, as well as identifying leading companies. The report also
provides a unique blend of qualitative analysis combined with extensive
quantitative data including global, submarket and national markets forecasts
from 2012-2022 - all highlighting key business opportunities.
Why you should buy Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022
93 pages of comprehensive analysis
3 Exclusive Visiongain interviews with experts from:
Zogenix
Bioject Medical Technologies
Glide Pharma
38 tables, charts, and graphs
Global Needle-Free Injection Device market forecast between 2012-2022
2 Needle-Free Injection Device submarket forecasts from 2012-2022
Jet Injectors
Competing Technologies
A SWOT analysis
Several leading companies identified and 14 profiled: Zogenix, Bioject,
Activa, J-Tip, Medical International Technology, Eurojet Medical, Pharmajet,
D'Antonio Consultants, Glide Pharma, Crossject, Valeritas, Akra Dermojet,
Penjet, Antares Pharma.
You can order this report today
Gain an understanding of the overall NFI device market and the leading
companies operating in this market by ordering Medical Device Leader Series:
Top Needle-Free Injection Device Manufacturers 2012-2022.
Visiongain is a trading partner with the US Federal Government.
Table of Contents
Table of Contents
1. Executive Summary
1.1. Leading NFI Device Manufacturers: Overview of Findings
1.2. Chapter Outline
1.3. Research and Analysis Methods
1.4. Aims, Scope and Format of the Report
1.5. Glossary of Terms Related to the Report
2. Introduction to Needle-Free Technology
2.1. What is Needle-Free Delivery?
2.1.1. History
2.2. Current Needle-Free Devices
2.3. Rationale for Needle-Free Injections
2.4. Applications of Needle Free Drug Delivery
2.4.1. Pain Management
2.4.2. Vaccine Delivery
2.4.3. Insulin Delivery
2.4.4. Paediatrics
2.5. Regulation of Needle-Free Delivery Devices
2.5.1. The US Regulation System
2.5.2. The European Regulation System
2.6. Advantages And Disadvantages of Needle Free Systems
3. The Global Needle Free Injection Device Market, 2011-2022
3.1. The Global Needle-Free Injection Device Market, 2011
3.1.1. The Global Needle Free Injection Device Market Forecast, 2012-2022
3.1.2. Needle-Free Injection Devices: Industry Trends, 2012-2022
3.2. The Jet Injector Device Market, 2011
3.2.1. The Global Jet Injector Device Market Forecast, 2012-2022
3.2.2. Jet Injector Devices: Industry Trends, 2012-2022
3.3. The Global Competing Technologies Market, 2011
3.3.1. The Global Competing Technologies Market Forecast, 2012-2022
3.3.2. Competing Technologies: Industry Trends, 2012-2022
3.3.2.1. Microneedle Technology
3.3.2.2. Metered Dose Inhalers
4. The Leading North American Needle-Free Injection Device Manufacturers, 2012
4.1. Antares Pharma
4.1.1. Sales and Recent Performance Analysis, 2011
4.1.1.1. Product Sales
4.1.2. Technology
4.1.2.1. Pressure Assisted Injection Devices
4.1.2.2. Transdermal Gel System
4.1.3. Products
4.1.3.1. Vision
4.1.3.2. Vibex
4.1.3.3. Pen Injector
4.1.4. Pipeline Technologies
4.1.4.1. Vibex MTX
4.1.5. Manufacturing
4.2. Bioject Medical Technologies
4.2.1. Sales And Recent Performance Analysis, 2011
4.2.2. Technology
4.2.3. Products
4.2.3.1. Biojector 2000
4.2.3.2. Vitajet
4.2.3.3. ZetaJet
4.2.4. Pipeline Technologies
4.2.4.1. Intradermal Pen Injector
4.2.4.2. Iject
4.2.4.3. Jupiter Jet
4.2.5. Manufacturing
4.2.6. Collaborations
4.2.6.1. MPI Research
4.2.6.2. World Health Organisation (WHO)
4.3. Zogenix
4.3.1. Sales and Recent Performance Analysis, 2011
4.3.2. Technology
4.3.2.1. Applications
4.3.3. Products
4.3.3.1. Sumavel DosePro
4.3.4. Pipeline Technologies
4.3.4.1. Relday
4.3.5. Collaborations
4.3.6. Manufacturing
4.4. Activa Brand Products, Inc.
4.4.1. Technology
4.4.2. Products
4.4.2.1. Product Advantages
4.4.2.2. Product Indications
4.5. D'Antonio Consultants International Inc. (DCI)
4.5.1. Products
4.5.1.1. LectraJet
4.5.2. Pipeline Technologies
4.5.2.1. Low Workload Jet Injector
4.5.2.2. Multi Channel Jet Injector (Simultaneous Vaccine Delivery)
4.6. National Medical Products, Inc.
4.6.1. Products
4.6.1.1. J-Tip
4.6.2. Advantages of the J-Tip System
4.7. Medical International Technologies (MIT)
4.7.1. Products
4.7.1.1. MED-JET
4.7.2. Increased Awareness Through Globalisation
4.8. Penjet Corporation
4.8.1. Products
4.8.1.1. Penjet
4.8.2. Applications
4.8.2.1. Multi-Component Drugs
4.8.2.2. Lyophilisation
4.8.2.3. Small Pox Vaccination
4.9. PharmaJet
4.9.1. Technology
4.9.2. Products
4.9.2.1. STRATIS
4.9.3. Applications
4.9.4. Collaborations
4.10. Valeritas
4.10.1. Products
4.10.1.1. Mini-Ject
5. The Leading European Needle-Free Injection Device Manufacturers, 2012
5.1. Akra Dermojet
5.1.1. Products
5.1.1.1. Dermojet "HR"
5.1.1.2. DERMOJET Polymedical
5.1.1.3. Automatic DERMOJET
5.2. Crossject Medical Technology
5.2.1. Technology
5.2.2. Products
5.2.2.1. Zeneo
5.3. Eurojet Medical
5.3.1. Products
5.3.1.1. E-Jet 100
5.4. Glide Pharma
5.4.1. Products/Technology
5.4.1.1. Glide SDI
5.4.1.2. Applications
5.4.2. Advantages
5.4.2.1. Injecting Solid Formulations
5.4.2.2. Pharmaceutical Companies
6. SWOT Analysis of the Needle Free Injection Device Market, 2012
6.1. Needle Free Injection Devices: Industry Trends
6.1.1. Drivers
6.1.1.1. Move Towards Safer Alternatives
6.1.1.2. Patent Expiry Will Increase Competition
6.1.1.3. Booming Global Vaccines Market
6.1.2. Restraints
6.1.2.1. Expensive Technology
6.1.2.2. Limited Clinical Data
6.1.2.3. Regulatory Bodies
6.2. SWOT Analysis of the Needle-Free Delivery Market
6.2.1. Strengths
6.2.1.1. Reduced Pain on Injection
6.2.1.2. No Specialist Training Required For Delivery
6.2.1.3. Reduction in Transport Costs
6.2.2. Weaknesses
6.2.2.1. Inefficient Manufacturing Process
6.2.2.2. Off Patent/Generics Require Reformulating
6.2.3. Opportunities
6.2.3.1. Emerging Economies
6.2.3.2. Mass Immunisation Programs
6.2.4. Threats
6.2.4.1. Inexpensive Needles and Syringes
6.2.4.2. Limited Clinical Data
7. Opinions from Our Industry Survey
7.1. Interview with Zogenix Technologies
7.1.1. The Needle-Free Injection Device Market
7.1.2. Zogenix's Portfolio/Technology
7.1.3. The Future Needle-Free Injection Device Market
7.2. Interview with Bioject Medical Technologies
7.2.1. Current Market for Needle Free Injection Technologies
7.2.2. Current Technologies
7.2.3. Future Prospects for the Industry
7.3 Interview with Glide Pharma
7.3.1. Growth of the Needle Free Market
7.3.2. Glide SDI and Other Technologies
7.3.3. Market Demand and Future Outlook
8. Conclusions
8.1. Zogenix Dominated the NFI Device Market in 2011
8.2. The Rise of Generics
8.3. Strong Pipeline Will Help Drive the Market
8.4. Concluding Remarks
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1: Examples Of Needle-Free Vaccine Delivery Systems, 2012
Table 2.2: Examples Of Needle-Free Insulin Delivery Systems, 2012
Table 2.3: Advantages & Disadvantages of Needle-Free Injection, 2012
Table 3.1: Net Sales ($bn) and Market Shares (%) Of The Global Needle-Free
Injection Device Market, By Technology, 2011
Table 3.2: Global Needle-Free Injection Devices: Market Forecast ($bn),
2011-2022
Table 3.3: Classification of Jet Injector Devices, 2012
Figure 3.5: Global Competing Needle-Free Technologies: Market Forecast
($bn), 2011-2022
Figure 4.1: Antares Pharma: Market Shares (%), By Business, 2011
Figure 4.2: Antares Pharma: Net Sales ($m), By Product Group, 2011
Figure 4.3: Antares Pharma: Market Shares (%), By Product, 2011
Figure 4.4: Antares Pharma: Net Sales ($m), By Quarter, 2011
Figure 4.5: Bioject: Net Sales ($m), By Product Line, 2010
Figure 4.6: Bioject: Market Share (%), By Product Line, 2010
Figure 4.7: Bioject: Market Shares (%), By Geography, 2010
Figure 4.8: Bioject: Total Net Sales ($m), 2006-2011
Figure 4.9: Zogenix: Net Sales ($m), By Business, 2011
Figure 4.10: Zogenix: Market Shares (%), By Business, 2011
Figure 4.11: Zogenix: Net Sales ($m), By Quarter, 2011
Figure 6.1: The Transport Process for A Vaccine
Figure 8.1: Net Sales ($m) for Zogenix, Antares Pharma & Bioject, 2011
Companies Listed
Activa (Advantajet)
Akra Dermojet
Antares Pharma
Astellas Pharma
AstraZeneca
Battelle
Bioject Medical Technologies
BioValve Technologies
Bristol-Myers Squibb
Covidien
Crossject Medical technology
D'Antonio Consultants International
Diabetes Management International
Dr. Reddy's Laboratories
Durect
Echo Therapeutics
Eli Lilly & Co
Eurojet Medical
Ferndale Pharma Group
Ferring Pharmaceuticals
Glide Pharma
GlaxoSmithKline (GSK)
JCR Pharmaceuticals
Mallinckrodt
Medical International Technologies
Merck Serono
MGlas AG
Minnesota Rubber and Plastics (MRP)
MPI Research
National Medical Products
Nektar Therapeutics
Nova Nordisk
Novartis
Nypro Limited
Patheon
Penjet Corporation
Pfizer
PharmaJet
Sanofi-Pasteur
Takeda
Teva Pharmaceuticals
Valeritas
Zogenix
Government Agencies and Other Organisations Mentioned in This Report
FDA
WHO
UN
CDRH
EU
USAMRIID
PATH
CDC
Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022 published by Visiongain in September 14, 2012. This report consists of 99 Pages and the price starts from US $ 2739.
The contents of this page may be different from the latest version. Please contact us for details.
